Fig. 6
EF1α-mEPO transposon-modified T lymphocytes raise hematocrit in vivo. a Schematic representation of experiment evaluating ability of adoptively transferred transposon-modified T cells to raise hematocrit in WT C57Bl6 mice. Red cells indicate OT-1 (red) or wild-type CD8+ T cells transfected with pT-ef1α-mEPO and pCMV-m7pB. b Plot of mean hematocrit measurements observed in mice that received 2 × 107 pT-EF1α-mEPO genome-modified wild-type T cells (black) or OT-1 T cells (red), and an i.v. OT-1 T-cell vaccine. Additional i.p. T-cell vaccines were administered (red arrow) on days 7 and 14, and then again on days 84 and 91 (OT-1 group) after initial transfer. Statistical analysis of hematocrit measurements were performed by comparing to pre-ACT levels using the Student’s T-test (N = 5 ± SEM, *p ≤ 0.01). The mean hematocrit for untreated mice was 47 ± 1.4 (N = 6 ± SEM). c Plot of mean hematocrit measurements of mice subjected to adenine-induced anemia. Mice treated with EF1α-mEPO transposon-modified T lymphocytes achieved a mean hematocrit > 42 by 2 weeks post ACT compared to a mean hematocrit of 34 for the untreated group. N = 5 ± SEM for ACT-treated (red) and N = 3 ± SEM for untreated (black). *p < 0.05 using the Student’s T-test comparing treated to untreated groups at week 0 and 6
